|Bid||4,694.00 x 200|
|Ask||4,697.00 x 34100|
|Day's Range||4,660.00 - 4,867.00|
|52 Week Range||38.20 - 4,867.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||1.36 (7.11%)|
|1y Target Est||28.00|
Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the "transformative deal" needed for a core generics comeback. Next year looks possible for recovery, but what of Teva's long-term revival?
Antares Pharma’s gross profit margins reached 45.0%, 57.0%, and 58.0% for fiscal 2016, fiscal 2015, and fiscal 2014, respectively.
U.S. fund investors walloped high-yield funds with their biggest week of withdrawals since March, Lipper data showed on Thursday. The "junk" bond mutual funds and exchange-traded funds posted $4.4 billion in net withdrawals during the week ended Nov. 15, the fourth largest weekly outflow on record dating to 1992. A stew of concerns hurt high-yield markets during the week, but the extensive withdrawals signal that investor sentiment may have been chief among them.
Does the share price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. AnyoneRead More...
Billionaire Israel "Izzy" Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with volatile fire in the market: Teva Pharmaceutical (NYSE:TEVA) and Valeant Pharmaceuticals (NYSE:VRX). However, the hedge fund guru is doing away with almost all of ACADIA Pharmaceuticals (NASDAQ:ACAD), a stock that has attracted mostly bullish attention on the Street.
Announcement: Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights. Global Credit Research- 16 Nov 2017. Hong Kong, November 16, 2017-- Moody's Investors Service ...
Shares of generic and specialty drug producer Teva Pharmaceutical (TEVA) jumped 7% Wednesday afternoon as investors get more hopeful about the future. Jefferies analysts met with Teva executives in Israel including the head of research and development, and concluded in a fresh report today that new CEO Kare Schultz may discuss strategy with investors by the end of the year, to coincide with quarterly results. Jefferies analysts David Steinberg, Edward Chung and Anthony Baldor gleaned in meetings that cost cutting and asset sales are "on the table" for Teva, with $35 billion in debt, high leverage and weakening profitability over time.
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch of a prescription copay assistance program in the U.S.
In support of the $675 million deal, Greg Bradley joined Foundation Consumer Healthcare as president and chief executive.
Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove themselves, before the Israeli pharma giant can make a comeback- at least in the eyes of Cantor analyst Louise Chen.
Is Teva Pharmaceutical (NYSE:TEVA) overpriced? For a company that just released a third quarter print, Oppenheimer analyst Derek Archila does not have any sense of improved conviction on the beleaguered biotech giant's growth arc.
Rating Action: Moody's assigns B2 CFR to IWH UK Finco Limited. Global Credit Research- 14 Nov 2017. London, 14 November 2017-- Moody's Investors Service, has today assigned a B2 Corporate Family rating ...
Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker. Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co unit - acting as a dealer for the shares - sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA )'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. ...
It was just two months ago that Teva Pharmaceutical Industries (TEVA) hired Kare Schultz as its new CEO, ending months of speculation about who would be tasked to steer the troubled specialty drug maker. Yes, hiring Schultz was a good move, Schott says. While Teva’s recent appointment of Kare Schultz as President and CEO (joined Nov 1) represents a clear positive in our view, adding a highly creditable executive with significant industry experience, we do not see any quick fixes for Teva... Overall, we believe Kare Schultz has the right background/experience set to evaluate and execute on restructuring opportunities in the Teva portfolio having successfully implementing a two-year restructuring program at Lundbeck with cost reductions exceeding expectations.
Shares of Teva Pharmaceutical Industries Ltd. shed 2.2% in premarket trade Monday, after the generic drug maker was downgraded at J.P. Morgan to a rare bearish rating, citing concerns over the U.S. generics ...
Teva Pharmaceutical (NYSE:TEVA) investors have seen a once strong Israeli pharma giant stumble 71% from its former valuation glory, and some on the Street fear another 50% fall from grace is still coming investors' way. HSBC analyst Steve McGarry and Wells Fargo analyst Davis Maris prepare for the worst.
Teva Pharmaceutical Industries’s stock slid 6% and its bonds dropped several points Tuesday, after Fitch Ratings downgraded the credit to junk, following disappointing earnings last week.
Late yesterday, Fitch cut Teva’s debt rating to junk, making it the first of the three major credit ratings agencies to strip the generic drug maker of its investment-grade status. According to Theflyonthewall.com, HSBC analyst Steve McGarry cut his rating on the stock to a Reduce and slashed his price target on the stock from $26 a share to $6 a share, arguing that the drug maker’s balance sheet is “over-stretched”. In short, McGarry sees Teva’s U.S.-listed shares falling another 50% in the next year, having already lost 71% over the past 12 months.
The market has divided itself into two camps. The bulls argue that the worst is behind Teva Pharmaceutical (NYSE:TEVA) as it started focusing on getting the business growing again. The bears argue that the market is too optimistic about Teva's recovery, which could take a long, long time. Goldman Sachs analyst Jami Rubin has found himself in the middle.
Generic drug prices are falling in the U.S. The company has a pile of debt from its 2016 acquisition of Actavis’s generic drug business. Add it all together and it’s a recipe for a junk credit rating...or at least the analysts at Fitch Ratings think so. Late yesterday, the firm became the first of the three major credit ratings agencies to cut Teva’s debt rating to junk, downgrading the drug maker to BB from BBB- with a negative outlook.
Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.